Baharnoori, Moogeh
Bhan, Virender
Clift, Fraser
Thomas, Kimberly
Mouallif, Soukaïna
Adlard, Nicholas
Cooney, Philip
Blanchette, François
Patel, Barkha P.
Grima, Daniel
Funding for this research was provided by:
Novartis Pharmaceuticals Canada
Article History
Accepted: 7 August 2022
First Online: 15 September 2022
Declarations
:
: This work was supported by Novartis Pharmaceutical Canada Inc.
: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SM and FB are employees of Novartis Pharmaceutical Canada Inc. KT, BPP and DG are employees of CRG-EVERSANA Canada Inc., which received funding from Novartis Pharmaceutical Canada Inc. to conduct this analysis. NA is an employee of Novartis International AG. PC is an employee of Novartis Ireland Limited. VB has received compensation for activity with Biogen, BMS, Celgene, EMD Serono, Genzyme, Novartis, Roche, Sanofi, and Teva. MB has received compensation for advisory board/consulting services to Alexion, Biogen, BMS, EMD Serono, Novartis, Pendopharm, Genzyme, Teva Neuroscience, Roche, and Xfacto communications. FC has received compensation for activity with Biogen, BMS, Celgene, EMD Serono, Genzyme, Novartis, Roche, Sanofi, and Teva.
: The economic model used for analyses is not publicly available at this time.
: Not applicable.
: Not applicable.
: Not applicable.
: SM, FB, KT, and DG contributed to the study conception and design. KT, BPP, and DG contributed to data analysis. MB, VB, and FC contributed to clinical interpretation of the data. The first draft of the manuscript was written by KT and BPP and all authors reviewed the manuscript, made substantial contributions to the content, and approved the final draft.